Palbociclib plus endocrine therapy in HR+/HER2- Advanced Breast Cancer patients: Interim Results of the PERFORM study 10. November 2023 Radosa J., Fietz T., Wilke J., Decker T., Petersen V., Deryal M., Knoblich J., Losem C., Rhein U., Schöttker B., Wrobel D., Pfeiler G., Zanucco E., Buncke J., Frank M., Woerner S.M., Gratzke, K., Adams, A., Glastetter E., Bartsch R., Lux M.P. Download Evaluation of the metastatic colorectal cancer score (mCCS) in predicting outcome for patients with RAS wild-type metastatic colorectal cancer treated with first-line panitumumab plus FOLFIRI/FOLFOX: Updated interim results of the non-interventional study VALIDATE Reiser M, Marschner N, Uhlig J, Jacobasch L, Müller L, Schuch A, Serrer L, de Buhr RK, Siebenbach HU, Göhler T, Schröder J, Semsek D,… Weiterlesen Palbociclib versus ribociclib in first-line treatment of patients with hormone-receptor positive HER2 negative advanced breast cancer – real world outcome data from the German registry platform OPAL Thill M., Zahn M.-O., Welt A., Nusch A., Zaiss M., Engelken K., Kaltenecker G., Ringwald K., Gratzke K., Kruggel L., Jänicke M., Schulz H., Losem… Weiterlesen